3 stocks to help you retire early

Retirement planning requires a long-term view and these three shares could bring retirement a big step closer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

For most people, retiring early is a major goal in life. Investing in shares can help you to achieve that, but these three stocks could help you to do so a few years earlier than you expected.

AstraZeneca

AstraZeneca (LSE: AZN) has endured a challenging period due to its loss of patents on key, blockbuster drugs in recent years. This has caused a large fall in profitability, which has hurt investor sentiment to a degree. However, this weakening of investor sentiment has been more than offset by optimism towards AstraZeneca’s acquisition strategy. The company has made full use of its strong cash flow and sound finances to transform its pipeline so that it’s now all set to deliver positive growth over the medium-to-long term.

Allied to this is AstraZeneca’s income potential. It currently yields 4.1% and with dividends being covered 1.5 times, they’re very sustainable. This mix of income return plus the potential for strong growth from its new pipeline of treatments means that AstraZeneca could soar over the long run and help you retire early.

Compass

One thing that’s of great benefit to long-term investors is consistency. On this front, Compass (LSE: CPG) has huge appeal since it has an excellent track record of earnings growth. In fact, over the last five years its bottom line has increased in each year, with an annualised earnings growth rate of 8.3% during the period. This bodes well for its future returns, since it shows that it can operate in a range of economic conditions and still turn a rising profit.

The food services industry provides Compass with a relatively dependable financial outlook. That’s because demand is quite resilient and with the outlook for the UK economy being uncertain due in part to Brexit, this could cause investor sentiment towards Compass to improve. Its yield of 2.2% may be lower than the FTSE 100’s yield of 3.5%, but with dividends being covered 1.9 times by profit, there’s scope for shareholder payouts to rise by at least as much as profit over the long run.

Sainsbury’s

Although the UK retail sector faces an uncertain future, Sainsbury’s (LSE: SBRY) has the right strategy to perform well. Its pricing is simple and focuses on offering value for money rather than chasing low prices, while its acquisition of Argos owner Home Retail provides growth potential. The synergies between the two companies are significant and there are major cross-selling opportunities that could boost Sainsbury’s bottom line over the medium-to-long term.

Sainsbury’s yields 4.4% at the present time and its dividends are covered twice by profit. While dividend growth may be somewhat low in the near term due to the uncertain operating environment it faces, Sainsbury’s has significant headroom when making dividend payments and this could lead to a rapidly rising income return over the coming years. Therefore, it offers excellent total return potential and alongside Compass and AstraZeneca, could help you retire early.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of AstraZeneca and Sainsbury (J). The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »